Clinical trials
Advanced Malignancies clinical trials
Below are recruiting advanced malignancies clinical trials, each written for real people, not researchers. We’re tracking 337 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07340190RecruitingPhase 1
How pelabresib affects other drugs in advanced cancer
This study tests how a new drug (pelabresib) interacts with other medicines like diabetes pills, a sedative, and birth control pills. It is for people with advanced cancer to help understand safe dosing.
BordeauxAges 18 years+ - NCT06038058RecruitingPhase 1
BRY812 for advanced solid tumors that have failed standard therapy
This trial tests an experimental drug called BRY812 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective against a protein called LIV-1 found on some cancer cells.
Guangzhou, GuangdongAges 18 years+ - NCT07644039RecruitingPhase 1/Phase 2
PM54 plus immunotherapy for advanced cancer
This study tests a new drug called PM54 combined with pembrolizumab (an immunotherapy) in people with advanced cancers that have gotten worse despite prior treatment. The goal is to see if this combination can slow or stop cancer growth.
New York, New YorkAges 18 years+ - NCT07130383RecruitingPhase 2
Study of two experimental drugs for advanced breast cancer and other solid tumors
This trial tests a combination of two investigational drugs, MHB036C and MHB039A, in people with advanced breast cancer or other solid tumors that have spread. The goal is to see if this combination can shrink tumors and help patients live longer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06468098RecruitingPhase 1
Study of IBI363 for advanced cancer
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04651348RecruitingPhase 1
Mil95 antibody study for relapsed or refractory cancers
This Phase 1 study tests a new antibody drug called MIL95 in people with cancers that have come back or did not respond to prior treatment. It focuses on checking safety and early signs of how well the treatment may work.
BeijingAges 18 years+ - NCT06937957RecruitingPhase 1
BR111 for advanced cancers
This is an early-phase study testing a new drug called BR111 for people with advanced solid tumors or B-cell lymphoma who have run out of effective options. The trial helps find the right dose and checks if the drug is safe.
Shanghai, Pudong New AreaAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT05039632RecruitingPhase 1/Phase 2
NBTXR3 plus radiation with anti-PD-1 for advanced lung or liver cancers
This study tests whether adding NBTXR3 (given into a tumor) and targeted radiation to anti–PD-1/PD-L1 immunotherapy can improve cancer control in advanced cancers that have spread to the lung and/or liver. Participants may be assigned to different radiation approaches to try to trigger tumor shrinkage in both treated and nearby or distant tumor areas.
Houston, TexasAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT06581419RecruitingPhase 1/Phase 2
Testing IAP0971 in advanced solid tumors and lung cancer
This trial tests a new drug called IAP0971 for people with advanced solid tumors or a specific type of lung cancer. It may help if your cancer has not responded to other treatments or if you have PD-L1-positive lung cancer that hasn't been treated yet.
Beijing, Beijing MunicipalityAges 18–75 - NCT07174661Recruiting
Planning ahead for teens and young adults with advanced cancer
This study tests an educational tool to help young adults with advanced solid tumors or high-grade brain tumors think about and discuss their future healthcare wishes early. It may help you feel more prepared and in control of your care.
Scottsdale, ArizonaAges 18–39 - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT05991583RecruitingPhase 1/Phase 2
IBB0979 for advanced solid tumors that have stopped responding to treatment
This trial tests an experimental drug called IBB0979 for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to find the right dose and see if the drug can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT05645276RecruitingPhase 1
Study of AK129 for advanced solid tumors
This Phase 1 study tests AK129 in people with advanced cancers that have spread. It looks for a safe dose and early signs the treatment may work, especially for tumors with measurable disease and needed prior treatment options.
Beijing, Beijing MunicipalityAges 18–75 - NCT06877650RecruitingPhase 1/Phase 2
Study of JMT108 for advanced solid tumors
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07043751RecruitingPhase 1
TQB6411 for advanced solid tumors
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
Beijing, Beijing MunicipalityAges 18–75 - NCT07338838RecruitingPhase 1
Testing TQB3142 in advanced tumors
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
Guangzhou, GuangdongAges 18–75 - NCT07123129RecruitingPhase 1
Study of SHR-7782 for advanced solid tumors
This trial tests a new drug called SHR-7782 for people with advanced cancers that have not responded to other treatments. It aims to see if the drug is safe and can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06383871RecruitingPhase 1
A study of the new drug HRS-7058 for advanced solid tumors
This is a phase 1 study testing a new oral drug called HRS-7058 for people with advanced solid tumors that have not responded to other treatments. The main goal is to find a safe dose and see how well the drug works.
Tianjin, Tianjin MunicipalityAges 18–75
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Advanced Malignancies trials by city
Studies with a site in or near these metro areas.
Advanced Malignancies trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for advanced malignancies?
- Yes. Clin2 currently lists 337 recruiting advanced malignancies studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignancies trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignancies trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.